Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [1] Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Enblad, M.
    Ghanipour, L.
    Cashin, P. H.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2018, 34 (08) : 1390 - 1395
  • [2] Peritoneal metastases from colorectal cancer: Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Riss, S.
    Mohamed, F.
    Dayal, S.
    Cecil, T.
    Stift, A.
    Bachleitner-Hofmann, T.
    Moran, B.
    EJSO, 2013, 39 (09): : 931 - 937
  • [3] Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases focused on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Jeon, Youngbae
    Park, Eun Jung
    EWHA MEDICAL JOURNAL, 2023, 46
  • [4] Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases
    Ljunggren, Malin
    Nordenvall, Caroline
    Palmer, Gabriella
    EJSO, 2021, 47 (11): : 2865 - 2872
  • [5] Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases
    Mirnezami, Reza
    Moran, Brendan J.
    Harvey, Kate
    Cecil, Tom
    Chandrakumaran, Kandiah
    Carr, Norman
    Mohamed, Faheez
    Mirnezami, Alexander H.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (38) : 14018 - 14032
  • [6] Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?
    Baratti, Dario
    Kusamura, Shigeki
    Iusco, Domenico
    Cotsoglou, Christian
    Guaglio, Marcello
    Battaglia, Luigi
    Virzi, Salvatore
    Mazzaferro, Vincenzo
    Deraco, Marcello
    DISEASES OF THE COLON & RECTUM, 2018, 61 (09) : 1026 - 1034
  • [7] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era
    Kelly, Michael Eamon
    Murphy, Edward
    Keyes, Alan Martin
    Khan, Mohammad Faraz
    Bolger, Jarlath C.
    Grundy, Josh
    Conneely, John
    MacHale, John
    McCaffrey, John
    Cahill, Ronan
    Moran, Brendan
    Shields, Conor
    Mulsow, Jurgen
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (04) : 1373 - 1377
  • [8] Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases
    Chua, Terence C.
    Quinn, Liam E.
    Zhao, Jing
    Morris, David L.
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (02) : 81 - 88
  • [9] Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer
    Piso, Pompiliu
    Stierstorfer, Kathrin
    Gerken, Michael
    Klinkhammer-Schalke, Monika
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (11) : 1559 - 1567
  • [10] Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastases
    Shah, Rupen
    Gangi, Alexandra
    CLINICS IN COLON AND RECTAL SURGERY, 2024, 37 (02) : 90 - 95